Antithrombotic effects of recombinant human soluble thrombomodulin (rhs-TM) on arteriovenous shunt thrombosis in rats
✍ Scribed by Dr. Yoshikazu Aoki; Ryoichi Takei; Mitsunobu Mohri; Yasunori Gonda; Komakazu Gomi; Taisuke Sugihara; Takao Kiyota; Shuji Yamamoto; Torao Ishida; Ikuro Maruyama
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 412 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
We examined the antithrombotic effect of recombinant human soluble thrombomodulin (rhs‐TM) using an arteriovenous shunt thrombosis model and its influence on hemostasis in rats. Intravenous administration of rhs‐TM (0.5–4 mg/kg) significantly inhibited thrombus formation and prolonged ex vivo activated partial thromboplastin time (APTT) in a dose‐dependent manner. Thrombus formation was inhibited to the same extent in animals treated with heparin (25–200 U/kg) and in those treated with rhs‐TM (0.5–4 mg/kg), but heparin had a much stronger effect on prolonging APTT. In the hemorrhagic study using the rat template bleeding time method, rhs‐TM exhibited the prolongation of the bleeding time only at the highest effective dose (rhs‐TM; 4 mg/kg) of the thrombosis experiments. Thus, rhs‐TM exhibits the inhibitory effect on thrombus formation with less APTT prolongation in comparison with heparin and without significant pertubation of hemostasis. © 1994 Wiley‐Liss, Inc.